Goldie–Coldman and bevacizumab beyond disease progression

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Grothey, A. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26, 5326–5334 (2008).

Mellor, H. R. & Callaghan, R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81, 275–300 (2008).

Ho, Q. T. & Kuo, C. J. Vascular endothelial growth factor: biology and therapeutic applications. Int. J. Biochem. Cell Biol. 39, 1349–1357 (2007).

Jain, R. K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19, 7–16 (2005).

Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592–603 (2008).